CN113038969A - 包含茴三硫或其衍生物的环糊精复合物的药物组合物 - Google Patents

包含茴三硫或其衍生物的环糊精复合物的药物组合物 Download PDF

Info

Publication number
CN113038969A
CN113038969A CN201980072663.5A CN201980072663A CN113038969A CN 113038969 A CN113038969 A CN 113038969A CN 201980072663 A CN201980072663 A CN 201980072663A CN 113038969 A CN113038969 A CN 113038969A
Authority
CN
China
Prior art keywords
cyclodextrin
formula
day
composition
thione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980072663.5A
Other languages
English (en)
Chinese (zh)
Inventor
尼古拉斯·皮诺
埃尔·穆斯塔法·贝尔格斯
弗雷德里克·特平
安妮-盖雷·富尼亚尔
阿斯温·德雷马克
娜塔莎·奥杜雷
伊内·德科克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orphan Partners 2
Original Assignee
Orphan Partners 2
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orphan Partners 2 filed Critical Orphan Partners 2
Publication of CN113038969A publication Critical patent/CN113038969A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201980072663.5A 2018-09-06 2019-09-06 包含茴三硫或其衍生物的环糊精复合物的药物组合物 Pending CN113038969A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862727691P 2018-09-06 2018-09-06
EP18306172 2018-09-06
EP18306172.0 2018-09-06
US62/727,691 2018-09-06
PCT/EP2019/073873 WO2020049166A1 (en) 2018-09-06 2019-09-06 Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof

Publications (1)

Publication Number Publication Date
CN113038969A true CN113038969A (zh) 2021-06-25

Family

ID=67841092

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980072663.5A Pending CN113038969A (zh) 2018-09-06 2019-09-06 包含茴三硫或其衍生物的环糊精复合物的药物组合物

Country Status (11)

Country Link
US (1) US12295969B2 (https=)
EP (1) EP3846856A1 (https=)
JP (1) JP7362725B2 (https=)
KR (1) KR20210054540A (https=)
CN (1) CN113038969A (https=)
AU (2) AU2019336943A1 (https=)
BR (1) BR112021003997A2 (https=)
CA (1) CA3111886A1 (https=)
IL (1) IL281161B2 (https=)
MX (1) MX2021002611A (https=)
WO (1) WO2020049166A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114558004A (zh) * 2022-03-29 2022-05-31 奎马特里克斯有限公司 Qtx125药物制剂
CN115738757A (zh) * 2022-11-24 2023-03-07 中国海洋大学 一种基于磺丁基-β-环糊精离子传输通道的单价阳离子选择性分离膜及其制备方法和应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022123038A1 (en) * 2020-12-10 2022-06-16 OP2 Drugs Anethole trithione administration regimen for the prevention or treatment of ischemia-reperfusion injuries
EP4112051A1 (en) * 2021-06-30 2023-01-04 Op2 Drugs Anethole trithione for the treatment of vasculitides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027970A2 (en) * 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
WO2017042267A1 (en) * 2015-09-08 2017-03-16 Orphan Partners 2 Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262165A (en) 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
CA2222133C (en) 1995-06-07 2002-12-24 Cygnus, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CN1771938A (zh) 2004-11-09 2006-05-17 胡才忠 茴三硫脂质体及其制备方法
BR112018004518A2 (pt) * 2015-09-08 2019-03-19 OP2 Drugs compostos para o tratamento de doenças ligadas à produção de espécies reativas de oxigênio (ros) mitocondriais
AU2018232799B2 (en) * 2017-03-07 2021-11-25 Centre Hospitalier Universitaire De Bordeaux Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027970A2 (en) * 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
WO2017042267A1 (en) * 2015-09-08 2017-03-16 Orphan Partners 2 Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GILLES DOLLO等: "Improvement in solubility and dissolution rate of 1, 2-dithiole-3-thiones upon complexation with β-Cyclodextrin and Its Hydroxypropyl and Sulfobutyl Ether-7 Derivatives", 《J PHARM SCI》, vol. 88, no. 9, 30 September 1999 (1999-09-30), pages 4 - 5 *
HONG-ZHEN YU等: "An Examination of the Potential Effect of Lipids on the First-Pass Metabolism of the Lipophilic Drug Anethol Trithione", 《 JOURNAL OF PHARMACEUTICAL SCIENCES》, vol. 100, no. 11, 30 November 2011 (2011-11-30) *
YING ZHENG等: "Physicochemical and Structural Characterization of Quercetin-b-Cyclodextrin Complexes", 《JOURNAL OF PHARMACEUTICAL SCIENCES》, vol. 94, no. 5, 31 May 2005 (2005-05-31), XP009506462, DOI: 10.1002/jps.20325 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114558004A (zh) * 2022-03-29 2022-05-31 奎马特里克斯有限公司 Qtx125药物制剂
CN114558004B (zh) * 2022-03-29 2023-08-11 奎马特里克斯有限公司 Qtx125药物制剂
CN115738757A (zh) * 2022-11-24 2023-03-07 中国海洋大学 一种基于磺丁基-β-环糊精离子传输通道的单价阳离子选择性分离膜及其制备方法和应用
CN115738757B (zh) * 2022-11-24 2024-03-29 中国海洋大学 一种基于磺丁基-β-环糊精离子传输通道的单价阳离子选择性分离膜及其制备方法和应用

Also Published As

Publication number Publication date
AU2019336943A1 (en) 2021-03-18
JP2021536472A (ja) 2021-12-27
IL281161B2 (en) 2024-01-01
KR20210054540A (ko) 2021-05-13
IL281161B1 (en) 2023-09-01
US20210308173A1 (en) 2021-10-07
BR112021003997A2 (pt) 2021-05-25
MX2021002611A (es) 2021-07-21
CA3111886A1 (en) 2020-03-12
IL281161A (en) 2021-04-29
AU2025204144A1 (en) 2025-06-26
EP3846856A1 (en) 2021-07-14
US12295969B2 (en) 2025-05-13
JP7362725B2 (ja) 2023-10-17
WO2020049166A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
JP7455917B2 (ja) 眼科用活性医薬成分送達のためのシクロデキストリン固体複合体の製造
CN113038969A (zh) 包含茴三硫或其衍生物的环糊精复合物的药物组合物
CN102362855B (zh) 一种伊曲康唑异构体口服溶液
TW202432120A (zh) 注射用組合物、包含其之醫藥調配物以及製備該組合物之方法
CN113018268B (zh) 一种注射用德拉沙星葡甲胺冻干制剂及其制备方法
CA3045226C (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
HK40097477A (en) Preparation of cyclodextrin nanoparticle for ophthalmic drug delivery
WO2017045603A1 (zh) 一种含喜树碱衍生物的注射制剂、其注射液、制备和应用
HK40015307A (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
HK40015307B (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination